Peter Greenleaf - Net Worth and Insider Trading

Peter Greenleaf Net Worth

The estimated net worth of Peter Greenleaf is at least $29 Million dollars as of 2026-09-11. Peter Greenleaf is the CEO of Aurinia Pharmaceuticals Inc and owns about 1,788,945 shares of Aurinia Pharmaceuticals Inc (AUPH) stock worth over $29 Million. Peter Greenleaf is the Director of Pelthos Therapeutics Inc and owns about 24,681 shares of Pelthos Therapeutics Inc (PTHS) stock worth over $553,595. Peter Greenleaf is also the CEO of Sucampo Pharmaceuticals Inc and owns about 2,513 shares of Sucampo Pharmaceuticals Inc (SCMP) stock worth over $45,234. Besides these, Peter Greenleaf also holds Avalo Therapeutics Inc (AVTX) . Details can be seen in Peter Greenleaf's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Peter Greenleaf has not made any transactions after 2026-04-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Peter Greenleaf

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

AUPH Aurinia Pharmaceuticals Inc

98% of holdings · $28.8M

PTHS Pelthos Therapeutics Inc

2% of holdings · $554K

AVTX Avalo Therapeutics Inc

SCMP Sucampo Pharmaceuticals Inc

0% of holdings · $45K

Peter Greenleaf Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Peter Greenleaf owns 9 companies in total, including BioDelivery Sciences International Inc (BDSI) , Antares Pharma Inc (ATRS) , and Avalo Therapeutics Inc (AVTX) among others .

Click here to see the complete history of Peter Greenleaf’s form 4 insider trades.

Insider Ownership Summary of Peter Greenleaf

Ticker	Company	Transaction Date	Type of Owner
BDSI	BioDelivery Sciences International Inc	2020-08-07	director
ATRS	Antares Pharma Inc	2022-05-24	director
AVTX	Avalo Therapeutics Inc	2018-05-18	director & Chief Executive Officer
		2018-07-10	director
		2018-02-13	Chief Executive Officer
		2015-11-05	director
		2016-03-01	director
		2025-03-04	director & Chief Executive Officer
		2026-04-02	director

Peter Greenleaf Latest Holdings Summary

Peter Greenleaf currently owns a total of 4 stocks. Among these stocks, Peter Greenleaf owns 1,788,945 shares of Aurinia Pharmaceuticals Inc (AUPH) as of March 4, 2025, with a value of $29 Million and a weighting of 97.96%. Peter Greenleaf owns 24,681 shares of Pelthos Therapeutics Inc (PTHS) as of April 2, 2026, with a value of $553,595 and a weighting of 1.88%. Peter Greenleaf also owns 2,513 shares of Sucampo Pharmaceuticals Inc (SCMP) as of November 29, 2016, with a value of $45,234 and a weighting of 0.15%. The other 1 stocks Avalo Therapeutics Inc (AVTX) have a combined weighting of 0.01% among all his current holdings.

Latest Holdings of Peter Greenleaf

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
AUPH	Aurinia Pharmaceuticals Inc	2025-03-04	1,788,945	16.11	28,819,904
PTHS	Pelthos Therapeutics Inc	2026-04-02	24,681	22.43	553,595
SCMP	Sucampo Pharmaceuticals Inc	2016-11-29	2,513	18.00	45,234
AVTX	Avalo Therapeutics Inc	2018-05-18	143	17.18	2,457

Holding Weightings of Peter Greenleaf

Peter Greenleaf Form 4 Trading Tracker

According to the SEC Form 4 filings, Peter Greenleaf has made a total of 5 transactions in Aurinia Pharmaceuticals Inc (AUPH) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Aurinia Pharmaceuticals Inc is the sale of 360,540 shares on March 4, 2025, which brought Peter Greenleaf around $3 Million.

According to the SEC Form 4 filings, Peter Greenleaf has made a total of 1 transactions in Pelthos Therapeutics Inc (PTHS) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Pelthos Therapeutics Inc is the sale of 797 shares on April 2, 2026, which brought Peter Greenleaf around $16,673.

According to the SEC Form 4 filings, Peter Greenleaf has made a total of 0 transactions in Sucampo Pharmaceuticals Inc (SCMP) over the past 5 years. The most-recent trade in Sucampo Pharmaceuticals Inc is the sale of 200,000 shares on November 29, 2016, which brought Peter Greenleaf around $3 Million.

More details on Peter Greenleaf's insider transactions can be found in the Insider Trading History of Peter Greenleaf table.

Insider Trading History of Peter Greenleaf

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Peter Greenleaf Trading Performance

GuruFocus tracks the stock performance after each of Peter Greenleaf's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Peter Greenleaf is 17.1%. GuruFocus also compares Peter Greenleaf's trading performance to market benchmark return within the same time period. The performance of stocks bought by Peter Greenleaf within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Peter Greenleaf's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Peter Greenleaf

Average Return

Average return per transaction

Outperforming Transactions

1 out of 2 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	20.43
Relative Return to S&P 500(%)	18.16

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Peter Greenleaf owns.

- AUPH - PTHS - SCMP - AVTX

View AUPH Analysis

Peter Greenleaf Ownership Network

Ownership Network List of Peter Greenleaf

No Data

Ownership Network Relation of Peter Greenleaf

Peter Greenleaf Owned Company Details

What does BioDelivery Sciences International Inc do?

Who are the key executives at BioDelivery Sciences International Inc?

Peter Greenleaf is the director of BioDelivery Sciences International Inc. Other key executives at BioDelivery Sciences International Inc include See Remarks James Vollins , See Remarks Mary Theresa Coelho , and director & Chief Executive Officer Jeffrey Allen Bailey .

BioDelivery Sciences International Inc (BDSI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BioDelivery Sciences International Inc (BDSI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioDelivery Sciences International Inc (BDSI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BioDelivery Sciences International Inc (BDSI)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioDelivery Sciences International Inc Insider Transactions

No Available Data

What does Antares Pharma Inc do?

Who are the key executives at Antares Pharma Inc?

Peter Greenleaf is the director of Antares Pharma Inc. Other key executives at Antares Pharma Inc include See Remarks Peter C Richardson , Executive Vice President & CFO Fred M Powell , and See Remarks Peter J Graham .

Antares Pharma Inc (ATRS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Antares Pharma Inc (ATRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Antares Pharma Inc (ATRS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Antares Pharma Inc (ATRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Antares Pharma Inc Insider Transactions

No Available Data

What does Avalo Therapeutics Inc do?

Who are the key executives at Avalo Therapeutics Inc?

Peter Greenleaf is the director & Chief Executive Officer of Avalo Therapeutics Inc. Other key executives at Avalo Therapeutics Inc include Chief Medical Officer Mittie Doyle , Interim CFO Christopher Ryan Sullivan , and Chief Strategy Officer Jennifer Riley .

Avalo Therapeutics Inc (AVTX) Insider Trades Summary

Over the past 18 months, Peter Greenleaf made no insider transaction in Avalo Therapeutics Inc (AVTX). Other recent insider transactions involving Avalo Therapeutics Inc (AVTX) include a net sale of 151,516 shares made by Mittie Doyle , a net sale of 171,205 shares made by Christopher Ryan Sullivan , and a net sale of 75,063 shares made by Paul Varki .

In summary, during the past 3 months, insiders sold 84,842 shares of Avalo Therapeutics Inc (AVTX) in total and bought 0 shares, with a net sale of 84,842 shares. During the past 18 months, 414,973 shares of Avalo Therapeutics Inc (AVTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 414,973 shares.

Avalo Therapeutics Inc (AVTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avalo Therapeutics Inc Insider Transactions

No Available Data

What does Kiora Pharmaceuticals Inc do?

Who are the key executives at Kiora Pharmaceuticals Inc?

Peter Greenleaf is the director of Kiora Pharmaceuticals Inc. Other key executives at Kiora Pharmaceuticals Inc include EVP of Finance Melissa Tosca , Chief Development Officer Eric Joseph Daniels , and director & President and CEO Brian M. Strem .

Kiora Pharmaceuticals Inc (KPRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kiora Pharmaceuticals Inc (KPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kiora Pharmaceuticals Inc (KPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kiora Pharmaceuticals Inc (KPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kiora Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sucampo Pharmaceuticals Inc do?

Who are the key executives at Sucampo Pharmaceuticals Inc?

Peter Greenleaf is the Chief Executive Officer of Sucampo Pharmaceuticals Inc. Other key executives at Sucampo Pharmaceuticals Inc include CFO Peter P. Pfreundschuh , Chief Science Officer Peter A Kiener , and Sr. Vice Pres. & BD & Licensing Jones W. Bryan .

Sucampo Pharmaceuticals Inc (SCMP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sucampo Pharmaceuticals Inc (SCMP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sucampo Pharmaceuticals Inc (SCMP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sucampo Pharmaceuticals Inc (SCMP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sucampo Pharmaceuticals Inc Insider Transactions

No Available Data

What does Savara Inc do?

Who are the key executives at Savara Inc?

Peter Greenleaf is the director of Savara Inc. Other key executives at Savara Inc include Chief Financial Officer David L Lowrance , Chief Medical Officer Yasmine Wasfi , and Chief Legal Officer Kathleen R. Mccabe .

Savara Inc (SVRA) Insider Trades Summary

Over the past 18 months, Peter Greenleaf made no insider transaction in Savara Inc (SVRA). Other recent insider transactions involving Savara Inc (SVRA) include a net purchase of 130,000 shares made by David A Ramsay , a net sale of 394,528 shares made by David L Lowrance , and a net purchase of 48,225 shares made by Richard J Hawkins .

In summary, during the past 3 months, insiders sold 394,528 shares of Savara Inc (SVRA) in total and bought 0 shares, with a net sale of 394,528 shares. During the past 18 months, 414,528 shares of Savara Inc (SVRA) were sold and 208,225 shares were bought by its insiders, resulting in a net sale of 206,303 shares.

Savara Inc (SVRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Savara Inc Insider Transactions

No Available Data

What does Synlogic Inc do?

Who are the key executives at Synlogic Inc?

Peter Greenleaf is the director of Synlogic Inc. Other key executives at Synlogic Inc include director & 10 percent owner Mohamad Makhzoumi , Head of Finance Mary Beth Dooley , and Chief Operating Officer Antoine Awad .

Synlogic Inc (SYBX) Insider Trades Summary

Over the past 18 months, Peter Greenleaf made no insider transaction in Synlogic Inc (SYBX). Other recent insider transactions involving Synlogic Inc (SYBX) include a net sale of 301 shares made by Mary Beth Dooley ,

In summary, during the past 3 months, insiders sold 0 shares of Synlogic Inc (SYBX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 301 shares of Synlogic Inc (SYBX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 301 shares.

Synlogic Inc (SYBX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Synlogic Inc Insider Transactions

No Available Data

What does Aurinia Pharmaceuticals Inc do?

Who are the key executives at Aurinia Pharmaceuticals Inc?

Peter Greenleaf is the director & Chief Executive Officer of Aurinia Pharmaceuticals Inc. Other key executives at Aurinia Pharmaceuticals Inc include EVP & General Counsel Stephen P. Robertson , 10 percent owner Tang Capital Management Llc , and Chief Financial Officer Michael S Hearne .

Aurinia Pharmaceuticals Inc (AUPH) Insider Trades Summary

Over the past 18 months, Peter Greenleaf made no insider transaction in Aurinia Pharmaceuticals Inc (AUPH). Other recent insider transactions involving Aurinia Pharmaceuticals Inc (AUPH) include a net purchase of 3,014,606 shares made by Kevin C Tang , a net sale of 20,975 shares made by Stephen P. Robertson , and a net sale of 20,000 shares made by Greg Keenan .

In summary, during the past 3 months, insiders sold 20,975 shares of Aurinia Pharmaceuticals Inc (AUPH) in total and bought 0 shares, with a net sale of 20,975 shares. During the past 18 months, 40,975 shares of Aurinia Pharmaceuticals Inc (AUPH) were sold and 3,014,606 shares were bought by its insiders, resulting in a net purchase of 2,973,631 shares.

Aurinia Pharmaceuticals Inc (AUPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aurinia Pharmaceuticals Inc Insider Transactions

No Available Data

What does Pelthos Therapeutics Inc do?

Who are the key executives at Pelthos Therapeutics Inc?

Peter Greenleaf is the director of Pelthos Therapeutics Inc. Other key executives at Pelthos Therapeutics Inc include director & 10 percent owner Ezra M Friedberg , Interim CEO & CFO & Treas & Sec Knuettel Ii Francis , and Chief Financial Officer John M. Gay .

Pelthos Therapeutics Inc (PTHS) Insider Trades Summary

Over the past 18 months, Peter Greenleaf made 1 insider transaction in Pelthos Therapeutics Inc (PTHS) with a net sale of 797. Other recent insider transactions involving Pelthos Therapeutics Inc (PTHS) include a net sale of 10,841 shares made by Ezra M Friedberg , a net sale of 1,572 shares made by Matthew Pauls , and a net purchase of 35,948 shares made by Todd C Davis .

In summary, during the past 3 months, insiders sold 1,627 shares of Pelthos Therapeutics Inc (PTHS) in total and bought 0 shares, with a net sale of 1,627 shares. During the past 18 months, 15,300 shares of Pelthos Therapeutics Inc (PTHS) were sold and 35,948 shares were bought by its insiders, resulting in a net purchase of 20,648 shares.

Pelthos Therapeutics Inc (PTHS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pelthos Therapeutics Inc Insider Transactions

No Available Data

Peter Greenleaf Mailing Address

Above is the net worth, insider trading, and ownership report for Peter Greenleaf. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Peter Greenleaf's mailing address is: Edmonton T5l 4s6.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.